Emerson to Automate First Large-Scale Biopharmaceutical Manufacturing Facility in South Korea.Business Editors/Health/Medical Writers/High-Tech Writers AUSTIN, Texas--(BUSINESS WIRE)--Oct. 20, 2003 Celltrion Inc. Contracts for Emerson's Life Sciences Solution and PlantWeb(R) Architecture Emerson Process Management, a business of Emerson (NYSE NYSE See: New York Stock Exchange :EMR (ElectroMagnetic Radiation) The emanation of energy from everything in the universe. Although the EMR from electrical and electronic devices is typically measured for practical, every-day situations, every object, including humans, emanates energy. ), has announced today that it will automate the first large scale biopharmaceuticals manufacturing facility in South Korea for Celltrion Inc. Emerson will provide engineering services and its PlantWeb(R) digital plant architecture to help streamline the 215,000-square-foot facility's manufacturing process, increasing output and reducing costs. In addition to benefiting from leading technology to improve operations, Celltrion officials said they selected Emerson for its life sciences experience. "We are confident and pleased to use Emerson's automation expertise and advanced technology to enable us to streamline our manufacturing process, increase its reliability and availability, and improve our consistency, quality and service," Celltrion senior vice president Dr. Hyun-Soo Lee said. Emerson's Asia Pacific Life Sciences Engineering Center in Singapore and system integrator in Korea will provide engineering design, configuration, documentation, site testing, commissioning and validation support. Emerson's PlantWeb architecture for Celltrion will include the DeltaV(tm) digital automation system, and AMS AMS - Andrew Message System (tm) Suite of predictive maintenance Predictive maintenance (PdM) techniques help determine the condition of in-service equipment in order to predict when maintenance should be performed. This approach offers cost savings over routine or time-based preventive maintenance because tasks are performed only when software. "Celltrion Inc. will benefit from high quality, throughput and better plant uptime like that achieved by other life sciences customers," said John Berra, president of Emerson Process Management. "We are proud to be selected as a partner to provide automation and validation services for what will be one of the largest and most technologically advanced biologic manufacturing facilities in Asia." The plant will house four 12,500-liter bioreactor bioreactor a container in which living organisms carry out a biological reaction. systems for clinical to commercial-scale production of protein-based pharmaceuticals that requires mammalian cell fermentation. It will be located on a 23-acre site in the rapidly developing technology park of Songdo New City in Inchon, South Korea. It will be initially equipped with a total bioreactor capacity of 50,000 liters and is designed to allow expansion to 150,000 liters. The facility will be ready for commercial operations in mid-2005, subject to regulatory approval. About Celltrion Inc. Celltrion Inc. (http://www.celltrion.com/) was founded in February 2002. It is a joint venture between VaxGen Inc. and a group of Korean partners, including Nexol Corp., Nexol Biotech Corp., KT&G Corp. and J. Stephen & Co. Ventures. Celltrion's major biologics manufacturing facility, a 23-acre site in Inchon, South Korea, will be used to manufacture VaxGen's AIDS vaccine AIDS vaccine A hypothetical vaccine intended to either prevent HIV infection or ensure that those infected will not fall victim to AIDS; the most promising vaccine is that using a naked DNA plasmid, reported by Letwin et al in 20/10/00 Science; as of early 2001, candidates, if licensed, and other biopharmaceutical products. The facility includes cGMP suites occupying 215,000 square feet for the production of vaccines, monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). and therapeutic proteins. It is scheduled to be ready for commercial operation by late 2005, following extensive facility testing and evaluation. About Emerson Process Management Emerson Process Management (http://www.emersonprocess.com) an Emerson business, is a leader in helping businesses automate their production, processing and distribution in the chemical, oil and gas, refining, pulp and paper, power, food and beverage F&B is a common abbreviation in the United States and Commonwealth countries, including Hong Kong. F&B is typically the widely accepted abbreviation for "Food and Beverage," which is the sector/industry that specializes in the conceptualization, the making of, and delivery of foods. , pharmaceutical and other industries. The company combines superior products and technology with industry-specific engineering, consulting, project management and maintenance services. Its brands include PlantWeb(R), Fisher(R), Micro Motion(R), Rosemount(R), DeltaV(tm), Ovation(R), AMS(tm) Suite, MDC (1) (Mobile Daughter Card) See riser card. (2) See Meta Data Coalition. and CSI CSI Crime Scene Investigator CSI CompuServe, Inc. CSI Commodity Systems, Inc. CSI Commodity Systems Inc. (Boca Raton, FL) CSI Crime Scene Investigation (CBS TV show) CSI Christian Schools International . About Emerson Emerson (http://www.gotoemerson.com) is a global leader in bringing technology and engineering together to provide innovative solutions to customers in process control; electronics and telecommunications; industrial automation; heating, ventilating ventilating Natural or mechanically induced movement of fresh air into or through an enclosed space. The hazards of poor ventilation were not clearly understood until the early 20th century. Expired air may be laden with odors, heat, gases, or dust. and air conditioning; and appliance and tools. Sales in fiscal 2002 were $13.8 billion. PlantWeb, Fisher, Micro Motion, Rosemount, DeltaV, Ovation and AMS are marks of Emerson Process Management. All other marks are properties of their respective owners. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion